House Bill Would Pay Drugmakers to Stockpile 6-Month Supply of Critical Medicines
Stalled
No legislative action in over 90 days.
How this policy affects specific groups of people
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
Bipartisan senators reintroduced the RAPID Reserve Act to address generic drug shortages by expanding domestic stockpiles and manufacturing capacity. The bill requires HHS to award contracts to U.S. or allied manufacturers to maintain reserves of essential medications and ingredients.
The Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act would require HHS to issue contracts to U.S.-based or OECD-based drugmakers to maintain reserves of critical medications and key ingredients, aiming to reduce overreliance on China and improve preparedness.
Authors argue that the RAPID Reserve Act is a 'legislative lifeline' designed to prevent 'pharmacological blackouts' by bringing critical medicine manufacturing back to U.S. shores and building strategic reserves of generic drugs currently dependent on Chinese and Indian supply chains.
Document Type
Congressional Bill
Official Title
RAPID Reserve Act
Analysis generated by AI. Always verify with official sources.